Neurodegenerative Diseases: Recent Advances and Future Perspectives, 2nd Edition

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 25 June 2025 | Viewed by 1073

Special Issue Editors


E-Mail Website
Guest Editor
1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
2. Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
Interests: visual science; neuroscience; optometry; ophthalmology; retina; neurodegeneration; dementia; glaucoma
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
2. Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
3. Department of Immunology, Ophthalmology and ENT, Faculty of Optics and Optometry, Complutense University of Madrid, 28037 Madrid, Spain
Interests: visual science; neuroscience; ophthalmology; retina; neurodegeneration; dementia; glaucoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the second volume of “Neurodegenerative Diseases: Recent Advances and Future Perspectives”.

Neurodegenerative disorders impact a significant portion of the global population, and their prevalence is increasing in tandem with rising life expectancies. Conditions such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, ataxias, and glaucoma are characterized by progressive neuronal deterioration and the disruption of neural connectivity, leading to impairment in mobility, coordination, strength, sensation, cognition, and vision.

These complex neurodegenerative ailments share underlying molecular and cellular features, including oxidative stress, mitochondrial dysfunction, protein misfolding, excitotoxicity, and inflammation. Despite ongoing research, definitive therapeutic interventions to cure or halt disease progression remain difficult to achieve. Consequently, investigations into early detection, disease onset, and innovative therapeutic strategies are paramount.

Research avenues encompass a wide range of methodologies, including animal models that reproduce pathological features, patient-derived pluripotent stem cell lines, organoid generation, and biomarker studies that assess retinal and ophthalmologic changes, protein profiles in various body fluids, and functional and structural assessments. These approaches are employed in both affected individuals and those at high genetic risk, contributing to a comprehensive understanding of disease mechanisms.

This Special Issue, under the direction of Dr. López-Cuenca and Dr. De Hoz, will highlight recent advances in the fields of basic, translational, and clinical research in neurodegenerative diseases. It aims at expanding knowledge on the pathophysiological mechanisms and therapeutic pathways for these disabling diseases.

Dr. Inés López-Cuenca
Dr. Rosa De Hoz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • neuroprotection
  • dementia
  • Parkinson’s disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1017 KiB  
Article
Dementia Deaths Most Commonly Result from Heart and Lung Disease: Evidence from the South Carolina Alzheimer’s Disease Registry
by Daniel A. Amoatika, John R. Absher, Md Tareq Ferdous Khan and Maggi C. Miller
Biomedicines 2025, 13(6), 1321; https://doi.org/10.3390/biomedicines13061321 - 28 May 2025
Viewed by 580
Abstract
Background: Cardiovascular disease (CVD) significantly impacts Alzheimer’s Disease and Related Dementia (AD/ADRD) mortality. South Carolina has a high incidence of CVD and dementia mortality. The aim of this study, therefore, was to examine the neurological causes of death and the leading causes of [...] Read more.
Background: Cardiovascular disease (CVD) significantly impacts Alzheimer’s Disease and Related Dementia (AD/ADRD) mortality. South Carolina has a high incidence of CVD and dementia mortality. The aim of this study, therefore, was to examine the neurological causes of death and the leading causes of death in the South Carolina Alzheimer’s Disease Registry (SCADR). Method: Data from 2005–2018 were extracted from the SCADR using ICD-9 and ICD-10 codes. The top 10 leading causes of death (LCOD) were identified using death certificates. Some neurological causes of death were operationalized by combining related ICD codes, such as CVD_C (I219, I251, I500, I64) and chronic obstructive pulmonary disease (COP_C), (J449, C349), and χ2 was used to compare socio-demographic characteristics and mortality. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) were estimated using extended Cox Proportional Hazard modeling, adjusting for socio-demographic factors. Results: A total of 207,093 registry cases were included in the analysis. About 70% of cases had Alzheimer’s Disease (AD) diagnosis, and 40% of all cases were 85 years and older. The LCOD was CVD_C (13.4%). The risk of death among cases with vascular dementia (VaD) was 1.17 times the risk of death among those with AD (aHR: 1.172, 95% CI: 1.148–1.196). Among all deaths, cases with COP_C had a significantly higher likelihood of death compared to those with CVD_C (aHR: 1.06, 95% CI: 1.025–1.090). Conclusions: The study highlights CVD_C as the LCOD in frequency, with survival analysis indicating COP_C risk of death as significantly higher compared to CVD_C deaths. There is a need to prioritize CVD and lung-related comorbidity prevention, assessment, and management programs for individuals living with ADRD. Full article
Show Figures

Figure 1

Back to TopTop